Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
6
SLS Quote, Financials, Valuation and Earnings
Last price:
$0.90
Seasonality move
:
2.47%
Day range:
$0.89 - $0.93
52-week range:
$0.50 - $1.72
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.99x
Volume:
1.1M
Avg. volume:
1.5M
1-year change:
-10.87%
Market cap:
$63.4M
Revenue:
--
EPS (TTM):
-$0.69
Analysts' Opinion
-
Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, SELLAS Life Sciences Group has an estimated upside of 547.72% from its current price of $0.91.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.91.
Fair Value
-
According to the consensus of 0 analysts, SELLAS Life Sciences Group has 547.72% upside to fair value with a price target of -- per share.
SLS vs. S&P 500
-
Over the past 5 trading days, SELLAS Life Sciences Group has overperformed the S&P 500 by 5.36% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
SELLAS Life Sciences Group does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
SELLAS Life Sciences Group has grown year-over-year revenues for 0 quarters straight. In the most recent quarter SELLAS Life Sciences Group reported revenues of --.
Earnings Growth
-
SELLAS Life Sciences Group has grown year-over-year earnings for 0 quarters straight. In the most recent quarter SELLAS Life Sciences Group reported earnings per share of -$0.10.
Enterprise value:
42.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-1.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | $900K | -- | -- | -- | -- | |
| Operating Income | -$38.4M | -$29.1M | -$32.8M | -$9.4M | -$7.3M | |
| EBITDA | -$38.4M | -$29.1M | -$32.8M | -$9.4M | -$7.3M | |
| Diluted EPS | -$2.22 | -$1.54 | -$0.69 | -$0.33 | -$0.10 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.3M | $29M | $22.6M | $5.2M | $24M | |
| Total Assets | $18.5M | $38M | $26M | $8.1M | $26.5M | |
| Current Liabilities | $4.2M | $5.3M | $12.6M | $11.7M | $10.6M | |
| Total Liabilities | $10.6M | $11.3M | $13.4M | $11.9M | $10.6M | |
| Total Equity | $7.9M | $26.6M | $12.6M | -$3.8M | $15.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$23.6M | -$31.7M | -$33.1M | -$6.9M | -$7.8M | |
| Cash From Investing | -- | -- | -- | -$3M | -- | |
| Cash From Financing | $23.2M | $19.9M | $50.1M | $54K | $19.7M | |
| Free Cash Flow | -$28.1M | -$37.2M | -$33.1M | -$9.9M | -$7.8M | |
SLS
Sector
Market Cap
$63.4M
$43.9M
Price % of 52-Week High
52.36%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-26.18%
-29.11%
Beta (5-Year)
2.391
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.89
200-day SMA
Sell
Level
$1.24
Bollinger Bands (100)
Sell
Level
1.08 - 1.32
Chaikin Money Flow
Sell
Level
-250.2M
20-day SMA
Sell
Level
$1.02
Relative Strength Index (RSI14)
Sell
Level
37.39
ADX Line
Sell
Level
7.18
Williams %R
Neutral
Level
-71.9214
50-day SMA
Sell
Level
$1.14
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
234.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Stock Forecast FAQ
In the current month, SLS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SLS average analyst price target in the past 3 months is --.
-
Where Will SELLAS Life Sciences Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that SELLAS Life Sciences Group share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About SELLAS Life Sciences Group?
Analysts are divided on their view about SELLAS Life Sciences Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that SELLAS Life Sciences Group is a Sell and believe this share price will drop from its current level to --.
-
What Is SELLAS Life Sciences Group's Price Target?
The price target for SELLAS Life Sciences Group over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for SELLAS Life Sciences Group is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SLS?
You can purchase shares of SELLAS Life Sciences Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase SELLAS Life Sciences Group shares.
-
What Is The SELLAS Life Sciences Group Share Price Today?
SELLAS Life Sciences Group was last trading at $0.90 per share. This represents the most recent stock quote for SELLAS Life Sciences Group. Yesterday, SELLAS Life Sciences Group closed at $0.91 per share.
-
How To Buy SELLAS Life Sciences Group Stock Online?
In order to purchase SELLAS Life Sciences Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is down 8.7% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 9.77% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is up 7.96% over the past day.
